SGC001, developed by Sungen Biomedical, received Fast Track Designation from the FDA. Currently, SGC001 is under clinical research for patients with AMI. Completed clinical trials in healthy individuals have demonstrated its favorable safety profile and tolerability. The FDA's Fast Track designation is expected to accelerate the commercialization of SGC001, thereby providing more effective treatment options for patients with AMI.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!